title: Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations.
abstract: OBJECTIVE
  Erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) frequently co-occur in men aged ≥40, along with lower urinary tract symptoms (LUTS) secondary to BPH. Given little real-world evidence on treatment use or satisfaction with treatment for concurrent BPH/LUTS and/or ED, this study examined medication regimens and differences in satisfaction and health-related quality of life (HRQoL) across regimens among men with concurrent BPH and ED.
  
  
  METHODS
  A cross-sectional study was conducted using an Internet survey of participants recruited through an online panel. Respondents (N=736) included men (aged ≥40) who self-reported a diagnosis of both ED and BPH with prescription treatment in the past 3 months for both conditions. Treatment satisfaction (eg, convenience and ease of planning) and HRQoL (eg, International Prostate Symptom Score, sleep quality) were self-reported. Generalized linear models examined the association of regimen with treatment satisfaction and HRQoL, adjusting for covariates (eg, age and comorbidities).
  
  
  RESULTS
  Final analyses included participants (N=507) using: tadalafil once-daily monotherapy (22%), tadalafil for ED with an alternate BPH therapy (36%), or another phosphodiesterase type-5 inhibitor (PDE5-I) combination (41%). These groups represented the major categories of treatment regimens found in the sample, excluded participants with ambiguous regimens, and were aligned with current standard of care for BPH and ED. Overall, patients reported moderate levels of BPH and a moderate-to-severe degree of ED. Tadalafil monotherapy patients had higher treatment satisfaction scores and greater reported ease of treatment planning and convenience than PDE5-I combination patients. No significant intergroup differences were found on HRQoL.
  
  
  CONCLUSIONS
  A majority of patients (59%) took tadalafil alone or in combination for BPH/ED treatment. Tadalafil monotherapy patients reported greater treatment satisfaction than patients taking PDE5-I combination therapy. Higher satisfaction for both effectiveness and convenience of once-daily tadalafil may inform both patient and clinician decisions regarding pharmacotherapy regimens.
authors.affiliation: Health Outcomes Practice, Kantar Health, New York, NY.
authors.forename: Lulu K
authors.initials: LK
authors.lastname: Lee
authors.affiliation: Health Outcomes Practice, Kantar Health, New York, NY.
authors.forename: Amir
authors.initials: A
authors.lastname: Goren
authors.affiliation: US Real World Outcomes Research, Eli Lily & Company, Indianapolis, IN.
authors.forename: Natalie N
authors.initials: NN
authors.lastname: Boytsov
authors.affiliation: US Real World Outcomes Research, Eli Lily & Company, Indianapolis, IN.
authors.forename: Craig F
authors.initials: CF
authors.lastname: Donatucci
authors.affiliation: Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA.
authors.forename: Kevin T
authors.initials: KT
authors.lastname: McVary
keywords: 5-alpha-reductase inhibitors; International Prostate Symptom Score; Treatment Satisfaction Questionnaire for Medication; alpha1-adrenergic blockers; once-daily tadalafil; treatment convenience; treatment satisfaction